Laparoscopic partial nephrectomy and percutaneous cryoablation for cT1 renal tumors are associated with similar 5-year rates of metastasis-free and overall and cancer-specific survival.
Atezolizumab plus cabozantinib was tolerable and demonstrated antitumor activity in patients with treatment-naïve, advanced ccRCC, according to a phase 1b study.
Gene signatures were identified as potential predictive biomarkers for outcomes with nivolumab among patients with advanced ccRCC in an analysis of the NIVOREN GETUG-AFU 26 trial.
Several gene signatures were associated with outcomes among patients with advanced clear cell RCC, but not non-clear cell RCC.
Treatment of patients with aRCC who are ineligible for nephrectomy with nivolumab plus ipilimumab improved outcomes compared with sunitinib, in a post hoc analysis of CheckMate 214.
Gene signatures were associated with response rate to nivolumab plus ipilimumab among patients with ccRCC, according to results of a phase 2 trial.
Compared with sunitinib alone, nivolumab plus cabozantinib therapy was associated with a 49% decreased risk for progression and 40% decreased risk for death.
Kidney microstructural features appear predictive of progressive CKD and mortality following radical nephrectomy.
Immunotherapy improved median overall survival by 7.5 months regardless of what other treatments patients received.
There is evidence to support the role of metastasectomy in providing patients with mRCC an improvement in certain clinical outcomes.